ALK and non-small cell lung carcinoma: We also included analysis of the ALK-G1269A mutant, which has not been reported in neuroblastoma, but which has been described as a highly resistant mutation arising in the EML4-ALK fusion oncoprotein in NSCLC patients treated with crizotinib25.